MENU
+Compare
IBRN
ETF ticker: NYSE ARCA
AS OF
Nov 13, 10:47 AM (EDT)
Price
$29.25
Change
+$0.02 (+0.07%)
Net Assets
4.38M

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Nov 12, 2025

IBRN sees MACD Histogram crosses below signal line

IBRN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 31 instances where the indicator turned negative. In of the 31 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for IBRN moved out of overbought territory on November 03, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on November 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRN as a result. In of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBRN broke above its upper Bollinger Band on October 20, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 41 cases where IBRN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in of 165 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 138 cases where IBRN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), Avadel Pharmaceuticals plc (NASDAQ:AVDL).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.71B. The market cap for tickers in the group ranges from 130.91M to 54.26B. ARGX holds the highest valuation in this group at 54.26B. The lowest valued company is CLYM at 130.91M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 29%. For the same ETF, the average monthly price growth was 248%, and the average quarterly price growth was 419%. ANRO experienced the highest price growth at 26%, while DYN experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was -21%. For the same stocks of the ETF, the average monthly volume growth was 49% and the average quarterly volume growth was 17%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 73
Price Growth Rating: 49
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 7 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com